Investment analysts at Morgan Stanley initiated coverage on shares of Indivior (OTCMKTS:INVVY – Get Rating) in a report released on Friday, The Fly reports. The firm set an “equal weight” rating on the stock. Separately, Zacks Investment Research upgraded shares of Indivior from a “hold” rating to a “buy” rating and set a $20.00 target […]
The FTSE 100 was flat on Wednesday as
gains in commodity stocks were offset by losses in retailers
following a spike in January inflation, while pharmaceutical
firm Indivior lifted the midcap index. | February 16, 2022
31.58%
Indivior PLC is close to a major resistance level, whereby the breach of this level could be considered as a buy signal. This reflects our preferred scenario in light of the stock s current technical chart pattern.
Investors have an opportunity to buy the stock and target the GBX 200.
Summary
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Strengths
Thanks to a sound financial situation, the firm has significant leeway for investment.
Its low valuation, with P/E ratio at 8.22 and 6.43 for the ongoing fiscal year and 2022 respectively, makes the stock pretty attractive with regard to earnings multiples.